Description
A selective progesterone receptor modulator (SPRM) that binds to human PR-A, PR-B, rabbit uterine PR, and rabbit thymic GR (EC50s = 8.5, 7.7, 13.6, and 15.4 nM, respectively); inhibits growth of IGROV-1 and SKOV3 human ovarian cancer cells (IC50s = 15.5 and 31.5 µM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed; reverses the proliferative effect of progesterone on patient-derived germ-line mutant BRCA1 breast tissue xenografts in ovariectomized athymic mice; inhibits ovulation in female mice when administered within 6 h of treatment with hCG (40 mg/kg, i.p.)